• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

26.59 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Today 9:00 EST
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
December 18, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
December 12, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
November 20, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
November 05, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
October 28, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
October 22, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 15, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
October 02, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
September 24, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
September 12, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 26, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
August 25, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
August 06, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 05, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
August 04, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
July 23, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
June 25, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
June 09, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
June 05, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 29, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
May 27, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
May 16, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
May 07, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
May 05, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap